Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

GSK to buy US biotech firm IDRx for up to $1.15 billion

Published by Global Banking and Finance Review

Posted on January 24, 2025

Featured image for article about Finance

(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour.

IDRx, a privately held biotechnology firm, is developing a therapy for the treatment of gastrointestinal stromal tumours.

The deal, which comprises an upfront payment of $1 billion, will add to GSK's growing portfolio in gastrointestinal cancers.

The British drugmaker, which has been grappling with a decline in its vaccines businesses, has stepped up its efforts in cancer treatment in recent years.

"This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical need, despite existing approved products," GSK's Chief Commercial Officer, Luke Miels, said in a statement.

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)